Reduction in Rotavirus-associated Acute Gastroenteritis Following Introduction of Rotavirus Vaccine Into Australia's National Childhood Vaccine Schedule

Buttery, Jim; Lambert, Stephen B.; Grimwood, Keith; Nissen, Michael D.; Field, Emma; Macartney, Kristine; Akikusa, Jonathan; Kelly, Janice M.; Kirkwood, Carl D.

doi:10.1097/inf.0b013e3181fefdee

Cited by 197 publications

(150 citation statements)

References 15 publications

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…16 Rotavirus vaccination in countries with established vaccination programmes has consistently and significantly reduced the incidence of rotavirus gastroenteritis (RVGE) and associated hospitalizations, emergency department visits and outpatient/physician office visits in the United States (US), Europe and Australia. [17][18][19][20] Belgium introduced rotavirus vaccination in November 2006, with an uptake of 85% in the first year 21 and 89% in the second year. 22 This high vaccine uptake is maintained throughout subsequent years where parents are asked for a co-payment of the vaccine of 11.6€ per dose.…”

Section: Introductionmentioning

confidence: 99%

Improvement in hospital Quality of Care (QoC) after the introduction of rotavirus vaccination: An evaluation study in Belgium

Standaert

Alwan²,

Strens

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

During each winter period hospital emergency rooms and pediatric wards are often overwhelmed by high patient influx with infectious diseases leading to chaotic conditions with poor quality of care (QoC) delivery as a consequence. The conditions could be improved if we were able to better control the influx by introducing for instance better prevention strategies against some of the most frequent infectious diseases. New prevention strategies using vaccination against rotavirus infection were introduced in Belgium in November 2006. We developed a measure of hospital QoC suitable for assessing the impact of pediatric rotavirus vaccination. The study is retrospective collecting routine data on bed and staff management in one pediatric hospital in Belgium. The data were divided in pre-and post-vaccination periods during rotavirus-epidemic and non-epidemic periods. The scores were constructed using Explanatory Factor Analysis (EFA). All patients enrolled were admitted to the pediatric ward over the period from 1 January 2004 to 31 December 2009. The results of the epidemic period indicated that bed-day occupancy, bed-day turnover and unplanned readmissions for acute gastroenteritis were lower in the post-vaccination compared with the pre-vaccination periods. The QoC scores were therefore significantly lower (indicating improved QoC) after the introduction of rotavirus vaccination, compared with pre-vaccination. The data suggests that the reduction in the winter peak of rotavirus-related hospitalizations after the introduction of the vaccine reduces pressure on hospital resources and improves the quality of hospital care. The findings should be further tested in similar settings.

show abstract

Section: Introductionmentioning

confidence: 99%

Improvement in hospital Quality of Care (QoC) after the introduction of rotavirus vaccination: An evaluation study in Belgium

Standaert

Alwan²,

Strens

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Clinical trials and post-marketing studies demonstrated high efficacy (81%-100%) of both vaccines in preventing severe RVGE in infants in developed countries, 9,10 and significant reduction in RVGE disease burden in settings that introduced rotavirus immunization programs. [11][12][13][14] Though the World Health Organization recommends routine rotavirus vaccination for infants worldwide, rotavirus immunization has been introduced into childhood immunization programs in only a limited number of countries. [15][16][17] Among the barriers to universal rotavirus immunization is skepticism regarding the need and potential benefit of rotavirus immunization in reducing RVGE disease burden, vaccine safety concerns, and cost issues.…”

Section: Introductionmentioning

confidence: 99%

A significant and consistent reduction in rotavirus gastroenteritis hospitalization of children under 5 years of age, following the introduction of universal rotavirus immunization in Israel

Muhsen

Rubenstein

Kassem

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Universal rotavirus vaccination with RotaTeq was introduced in Israel in December 2010. We examined hospitalization rates of children under 5 years of age due to all-cause and rotavirus gastroenteritis, both before and 3 years after universal introduction of the vaccination. An ongoing hospital-based surveillance network that was established in November 2007, accessed information regarding hospitalization of children due to gastroenteritis (n D 6205) in 3 hospitals in northern Israel, with an annual average of about 60,000 children under 5 years of age living in the catchment area of these hospitals. Stool samples were tested for rotavirus by immunochromatography. Compared to the period preceding implementation of the universal rotavirus vaccination (2008)(2009)(2010), hospitalizations due to rotavirus gastroenteritis in children <5 years of age decreased significantly, by 55% (95% CI 43%-67%) during the period of universal vaccination (2011-2013), a decrease that was sustained throughout the 3 year period. This reduction was greater in children aged 0-23 months (60-61%) than in toddlers aged 24-59 months (36%). A 32% (95% CI 21%-45%) decrease in the incidence of all-cause gastroenteritis was also observed. During the period preceding universal vaccination, rotavirus diarrhea showed typical winter seasonality, with highest incidence in December. However, the winter peak was substantially blunted during the period of universal immunization. Surveillance of rotavirus gastroenteritis should continue to assess the long-term impact of such a program. Our findings are of relevance to high and middle-income countries considering the introduction of a universal rotavirus immunization program.

show abstract

“…Vaccine effectiveness against gastroenteritis leading to hospitalization has been variable in NT; vaccine was estimated to be 77.7% effective during a 2007 G9P[8] outbreak ( 11 ) and 19% effective against a fully heterotypic G2P[4] strain in 2009 ( 12 ). Rotarix has been effective for decreasing rotavirus infection notification rates in Darwin, NT ( 10 ), and New South Wales ( 13 ). However, in 1 location in central NT, reported rotavirus infection rates have remained similar in the vaccine era to those in the prevaccine era ( 10 ), suggesting low vaccine uptake, low vaccine take, or waning immunity.…”

Section: Discussionmentioning

confidence: 99%

Novel G10P[14] Rotavirus Strain, Northern Territory, Australia

Cowley¹,

Donato²,

Roczo-Farkas³

et al. 2013

Emerg. Infect. Dis.

Self Cite

View full text Add to dashboard Cite

We identified a genotype G10P[14] rotavirus strain in 5 children and 1 adult with acute gastroenteritis from the Northern Territory, Australia. Full genome sequence analysis identified an artiodactyl-like (bovine, ovine, and camelid) G10-P[14]-I2-R2-C2-M2-A11-N2-T6-E2-H3 genome constellation. This finding suggests artiodactyl-to-human transmission and strengthens the need to continue rotavirus strain surveillance.

show abstract

Reduction in Rotavirus-associated Acute Gastroenteritis Following Introduction of Rotavirus Vaccine Into Australia's National Childhood Vaccine Schedule

Cited by 197 publications

References 15 publications

Improvement in hospital Quality of Care (QoC) after the introduction of rotavirus vaccination: An evaluation study in Belgium

Improvement in hospital Quality of Care (QoC) after the introduction of rotavirus vaccination: An evaluation study in Belgium

A significant and consistent reduction in rotavirus gastroenteritis hospitalization of children under 5 years of age, following the introduction of universal rotavirus immunization in Israel

Novel G10P[14] Rotavirus Strain, Northern Territory, Australia

Contact Info

Product

Resources

About